Founder & Executive Chairperson at Biocon
We launched liraglutide in the United States, Europe, and the United Kingdom. In India, the market for semaglutide was highly saturated, with forty-two companies launching products on day one. We decided to bypass that price war and focus on markets that offer better value.
This answer is part of a full interview with Kiran Mazumdar-Shaw, Founder & Executive Chairperson at Biocon.
Found this insight valuable? Share it with your network to help others learn from Kiran Mazumdar-Shaw's experience.
Use this answer in your research, article, or academic work
